Neoadjuvant Carboplatin/Paclitaxel versus 5-Fluorouracil/Cisplatin in Combination with Radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Comparative Study.

Cancers (Basel) · 2022 · PMC9179264 · PMID 35681592

Europe PMC DOI

hedged sentence

0.0830

closest p · 1.7× alpha

0.0830

boldest claim

The sentences

an unfavorable trendp = 0.083so close (0.05 < p ≤ 0.1)

Although pCR rates were consistent with our current results, this study showed an unfavorable trend for CROSS compared to PF (MST 32.7 versus 16.7 months, respectively, p = 0.083).

also in 104 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.